The global bronchitis clinical trials landscape reveals opportunities in optimizing trial locations, enhancing enrollment strategies, and investing in promising drugs. By analyzing trial phases, ...

The report highlights market opportunities by offering strategic insights into global rhabdomyosarcoma clinical trials. Key opportunities include identifying optimal locations for trials, ...

Xia, R. , Blimberg, C. , Sotelo, F. and Vandernaalt, Z. (2025) Effects of Aerobic Exercise on Physical, Mental, and Cognitive ...

"RethinkBH and Raintree are combining our strengths to deliver tools that meet the real-world needs of multidisciplinary therapy practices," said Rethink CEO Ben Semmes. "We want to make life easier ...

Company reports Q3 2025 AUCATZYL® net product revenue of $21.1 million and deferred revenue of $7.6 million; 60 authorized treatment centers achieved ahead of targetClinical execution and data ...

Extended-spectrum β-lactamase-producing Enterobacterales (ESBL-E) have become a critical global public health challenge due to their high resistance to β-lactam antibiotics and association with severe ...

Introduction Burnout and reduced well-being are highly prevalent among Japanese medical students during clinical training. Scalable, evidence-based interventions are urgently needed. This protocol ...

Cynata Therapeutics Limited ( OTCPK:CYYNF) Discusses Clinical Trial Progress and Corporate Developments Including GVHD, Osteoarthritis, and Kidney Transplantation November 5, 2025 8:30 PM EST ...

ORR in heavily pre-treated patients with MSS mCRC without liver metastases and with high plasma tumor mutational burden (TMB) Estimate 55% of patients with MSS CRC have high plasma TMB, representing a ...

ORR in heavily pre-treated patients with MSS mCRC without liver metastases and with high plasma tumor mutational burden (TMB)Estimate 55% of ...

Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on developing anti-inflammatory ...

End of Period Subscribers of 3.0 million, including Clinical Subscribers of 124 thousand Total Revenues of $172 million; Clinical Subscription ...